Additional file 1 of Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
Bibliographic record
Abstract
Additional file 1: Table S1. Changes from baseline in patient reported outcomes at week 52. Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection at week 0. Data shown as mean (SD) at baseline, and mBOCF (SD) at week 52. ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying anti-rheumatic drugs; IXE = ixekizumab; JSEQ = Jenkins Sleep Evaluation Questionnaire; mBOCF = modified baseline observation carried forward; N = number of patients in the analysis population; n = number of patients in each treatment subgroup; NRS = numeric rating scale; PtGA = patient global disease activity; Q = question; Q2W = every 2 weeks; Q4W = every 4 weeks; SD = standard deviation; TNFi = tumor necrosis factor inhibitor. Figure S1. Association between ASAS response and improvements in ASAS PROs for ixekizumab Q2W-treated patients after 52 weeks. Q2W ixekizumab-treated patients. § p<0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p<0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p<0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = (ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying antirheumatic drugs; LSM = least squares mean; mBOCF = modified baseline observation carried forward; Nx = number of observations; PROs = patient-reported outcomes; PtGA = patient global disease activity; Q = question; Q2W = every 2 weeks; SE: standard error; TNFi = tumor necrosis factor inhibitor. Figure S2. Association between ASAS response and improvements in ASAS PROs for ixekizumab Q4W-treated patients after 52 weeks. Q4W ixekizumab-treated patients. § p<0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p<0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p<0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = (ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying antirheumatic drugs; LSM = least squares mean; mBOCF = modified baseline observation carried forward; Nx = number of observations; PROs = patient reported outcomes; PtGA = patient global disease activity; Q = question; Q4W = every 4 weeks; SE = standard error; TNFi = tumor necrosis factor inhibitor. Figure S3. Association between ASAS response and improvements in other PROs for ixekizumab Q2W-treated patients after 52 weeks.Q2W ixekizumab-treated patients. § p<0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p<0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p<0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = (ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; bDMARD = biologic disease-modifying antirheumatic drugs; JSEQ = Jenkins Sleep Evaluation Questionnaire; LSM = least squares mean; mBOCF: modified baseline observation carried forward; NRS = numeric rating scale; Nx = number of observations; PROs = patient reported outcomes; Q = question; Q2W = every 2 weeks; SE = standard error; TNFi = tumor necrosis factor inhibitor. Figure S4. Association between ASAS response and improvements in other PROs for ixekizumab Q4W-treated patients after 52 weeks.Q4W ixekizumab-treated patients. § p<0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p<0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p<0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; bDMARD = biologic disease-modifying antirheumatic drugs; JSEQ = Jenkins Sleep Evaluation Questionnaire; LSM = least squares mean; mBOCF = modified baseline observation carried forward; NRS = numeric rating scale; Nx = number of observations; PROs = patient-reported outcomes; Q = question; Q4W = every 4 weeks; SE = standard error; TNFi = tumor necrosis factor inhibitor.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.026 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.002 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.857 | 0.130 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".